Evaluation of the Pharmacokinetic Profile, Pharmacodynamic Effects, Acceptability and Tolerability of an Oral Amiodarone Solution of 15 mg / mL in Children With Supra Ventricular Tachycardia

Inclusion Criteria: * Child (boy or girl) with supra ventricular tachycardia diagnosed by ECG recording. * Child aged 0 to 11 years. * Child whose parents / legal representative (s) agree to sign a consent form. * Child whose opinion / agreement has been / has been attempted to be collected. * Child and parents / legal representative (s) being ready and able to participate in the study, understanding and committing to respect the procedures of the study throughout its duration. * Child enrolled in a social security scheme. * Child with a body mass index between the 3rd and the 97th percentile. Exclusion Criteria: * A child with a known hypersensitivity to the active ingredient, iodine or any of the excipients of the study formulation. * Child who has already been treated with amiodarone (as a capsule or with the oral injectable form) * Impossibility of taking blood samples. * Hyperthyroidism (TSH \<laboratory low standard). * Disruption of liver function (ASAT\> 3N and / or ALT\> 3N). * Renal impairment (Cl creat \<30 mL / min) * Hepatic insufficiency (TP or factor V \<70%) * Inotropic support. * Uncorrected severe ionic disorders. * Extension of the QTc space before the implementation of the treatment (\> 450 ms). * Non-paired sinus disease. * Concomitant treatment with a drug which has an absolute contraindication with amiodarone. * Child with gastrointestinal disorders such as malabsorption syndrome. * Weight \<2.5 kg. * Child whose mother was treated with amiodarone during pregnancy. * Child who received another product under investigation or participated in another study within 60 days of the start of this study.